TY  - GEN
AU  - Alcaraz,A
AU  - González-López,R
AU  - Morote,J
AU  - de la Piedra,C
AU  - Meseguer,C
AU  - Esteban,E
AU  - Climent,M
AU  - González-Gragera,B
AU  - Alvarez-Ossorio,J-L
AU  - Chirivella,I
AU  - Mellado,B
AU  - Lara,P-C
AU  - Vázquez,F
AU  - Contreras,J-A
AU  - Carles,J
AU  - Murias,A
AU  - Calderero,V
AU  - Comet-Batlle,J
AU  - González-Del Alba,A
AU  - León-Mateos,L
AU  - Mañas,A
AU  - Segarra,J
AU  - Lassa,A
AU  - González-Enguita,C
AU  - Méndez,M-J
AU  - Samper,P
AU  - Unda,M
AU  - Mahillo-Fernández,I
AU  - Bellmunt,J
TI  - Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study
SN  - 1532-1827
PY  - 2013///0920
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Alkaline Phosphatase
KW  - blood
KW  - Biomarkers, Tumor
KW  - Bone Density Conservation Agents
KW  - therapeutic use
KW  - Bone Neoplasms
KW  - drug therapy
KW  - Bone Remodeling
KW  - Bone and Bones
KW  - enzymology
KW  - Carcinoma, Renal Cell
KW  - metabolism
KW  - Collagen Type I
KW  - Diphosphonates
KW  - Disease Progression
KW  - Female
KW  - Humans
KW  - Imidazoles
KW  - Kidney Neoplasms
KW  - Male
KW  - Middle Aged
KW  - Peptide Fragments
KW  - Procollagen
KW  - Prospective Studies
KW  - Treatment Outcome
KW  - Urinary Bladder
KW  - Urinary Bladder Neoplasms
KW  - Zoledronic Acid
N1  - Publication Type: Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1038/bjc.2013.272
ER  -